Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
A Novel Non-Invasive Eye Imaging Biomarker for Amyotrophic Lateral Sclerosis
FY 2021-22
Summary
Amyotrophic Lateral Sclerosis (ALS) is a fatal and incurable disease that causes motor neurons, which are responsible for controlling muscles, to deteriorate over time leading to progressive weakness. Current ALS diagnostic methods are expensive, inaccessible, and invasive procedures. A new non-invasive and widely accessible biomarker that can be used to diagnose and monitor ALS is an unmet need. A defining pathological feature of ALS is axonal spheroids, which are protein accumulations in motor neurons. We recently discovered the presence of axonal spheroids in the retina sections of deceased ALS patients. Therefore, we believe the eye can be used as a window into ALS pathology by monitoring these retinal spheroids. We propose to use confocal scanning laser ophthalmoscope (cSLO) and optical coherence tomography (OCT), widely available Health Canada-approved eye imaging devices, to develop a retinal imaging biomarker in 30 post-mortem eye specimens from ALS patients and 30 age-matched controls. We hypothesize that these retinal spheroids are a biomarker of neuronal injury and can be non-invasively imaged to monitor ALS progression. We will use cSLO and OCT, immunohistochemical markers to visualize spheroids in retina sections and hyperspectral microscopy to identify the optical and molecular properties of retinal spheroids. We will compare these data with clinical profile of patients to develop a model that can be used to monitor ALS progression. We will apply the same techniques to mouse model of ALS to determine if retinal spheroids exist in live animals and whether they can be used to monitor disease progression over time. A non-invasive and available imaging biomarker is significant as it can be used by clinicians to diagnose and monitor ALS.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466756
Name
Khorrami Farbod
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Novel Non-Invasive Eye Imaging Biomarker for Amyotrophic Lateral Sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Amyotrophic Lateral Sclerosis; Axonal Injury; Biomarker; Neurodegeneration; Retinal Imaging; Spheroids
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a fatal and incurable disease that causes motor neurons, which are responsible for controlling muscles, to deteriorate over time leading to progressive weakness. Current ALS diagnostic methods are expensive, inaccessible, and invasive procedures. A new non-invasive and widely accessible biomarker that can be used to diagnose and monitor ALS is an unmet need. A defining pathological feature of ALS is axonal spheroids, which are protein accumulations in motor neurons. We recently discovered the presence of axonal spheroids in the retina sections of deceased ALS patients. Therefore, we believe the eye can be used as a window into ALS pathology by monitoring these retinal spheroids. We propose to use confocal scanning laser ophthalmoscope (cSLO) and optical coherence tomography (OCT), widely available Health Canada-approved eye imaging devices, to develop a retinal imaging biomarker in 30 post-mortem eye specimens from ALS patients and 30 age-matched controls. We hypothesize that these retinal spheroids are a biomarker of neuronal injury and can be non-invasively imaged to monitor ALS progression. We will use cSLO and OCT, immunohistochemical markers to visualize spheroids in retina sections and hyperspectral microscopy to identify the optical and molecular properties of retinal spheroids. We will compare these data with clinical profile of patients to develop a model that can be used to monitor ALS progression. We will apply the same techniques to mouse model of ALS to determine if retinal spheroids exist in live animals and whether they can be used to monitor disease progression over time. A non-invasive and available imaging biomarker is significant as it can be used by clinicians to diagnose and monitor ALS.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khorrami, Farbod
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~